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graBACKGROUND The amyloid beta peptide is the major protein constituent of neuritic plaques in Alzheimer disease and
appears to play a central role in vascular inﬂammation pathophysiology.
OBJECTIVES This study sought to determine the clinical value of amyloid-beta 1-40 (Abeta40) measurement in pre-
dicting cardiovascular (CV) mortality in patients with coronary heart disease (CHD) and arterial stiffness progression in
young healthy subjects.
METHODS Abeta40 was retrospectively measured in blood samples collected from 3 independent prospective cohorts
and 2 case-control cohorts (total N ¼ 1,464). Major adverse cardiac events (MACE) were assessed in the 2 prospective
cohorts (n ¼ 877) followed for a median of 4.4 years. To look at effects on subclinical disease, arterial stiffness was
evaluated at baseline and after 5-year follow-up (n ¼ 107) in young healthy subjects. The primary endpoint was the
predictive value of Abeta40 for CV mortality and outcomes in patients with CHD.
RESULTS In Cox proportional hazards models adjusted for age, sex, estimated glomerular ﬁltration rate, left ventricular
ejection fraction, high-sensitivity C-reactive protein, and high-sensitivity troponin T, Abeta40 independently predicted
CV death and MACE in patients with CHD (p < 0.05 for all). After multivariate adjustment, Abeta40 levels conferred a
substantial enhancement of net reclassiﬁcation index and integrated discrimination improvement of individuals at risk in
the total combined CHD cohort over the best predictive model. Further cohort-based analysis revealed that Abeta40
levels were signiﬁcantly and independently associated with arterial stiffness progression, incident subclinical athero-
sclerosis, and incident CHD.
CONCLUSIONS Measuring blood levels of Abeta40 identiﬁed patients at high risk for CV death. (J Am Coll Cardiol
2015;65:904–16) © 2015 by the American College of Cardiology Foundation.m the *Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Athens, Greece; yMedizinische Klinik
d Poliklinik I, Ludwig-Maximilians-Universität München, Munich, Germany; zSecond Department of Cardiology, Attikon
spital, School of Medicine, University of Athens, Athens, Greece; xCardiology Clinic, Democritus University of Thrace, Alex-
droupolis, Greece; kDeutsches Herzzentrum, Technische Universität, Munich, Germany; {Institute of Cardiovascular Regen-
tion, Centre of Molecular Medicine, J.W. Goethe University Frankfurt, Frankfurt am Main, Germany; #Department of
rdiology, J.W. Goethe University Frankfurt, Frankfurt am Main, Germany; **Atherothrombosis Research Center/Department of
emistry, University of Ioannina, Ioannina, Greece; yyDepartment of Psychiatry and Psychotherapy, Technische Universität
nchen, Munich, Germany; zzDepartment of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany;
ection for Dementia Research, Hertie-Institute of Clinical Brain Research, Tübingen, Germany; kkDZNE, German Center for
urodegenerative Diseases, Tübingen, Germany; {{German Center of Cardiovascular Research, Frankfurt, Germany; and the
DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. This study was
pported by the Hirnliga e.V., “Nachwuchswissenschaftler 2011,” and “FFF-Innovation 2012” programs of the J.W. Goethe
iversity Frankfurt; the Excellence Cluster Cardio-Pulmonary System; the LOEWE Center for Cell and Gene Therapy
ate of Hessen); the German Cardiac Society; Else Kröner-Fresenius-Stiftung grant to Dr. Stellos; and Hellenic Cardiac Society
nts to Drs. Stakos and Stamatelopoulos. Drs. Rallidis and Tselepis were supported by the Hellenic Society of Lipidology,
AB BR E V I A T I O N S
AND ACRONYM S
Abeta40 = amyloid-beta 1-40
APP = amyloid precursor
protein
CHD = coronary heart disease
CV = cardiovascular
eGFR = estimated glomerular
ﬁltration rate
hsCRP = high-sensitivity
C-reactive protein
hsTnT = high-sensitivity
troponin T
IMT = intima media thickness
LVEF = left ventricular
ejection fraction
MACE = major adverse cardiac
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905P revention and risk management of atheroscle-rotic vascular disease complications, whichare the main causes of mortality and
morbidity, remain major health challenges, with a
tremendous socioeconomic impact on Western soci-
eties. Identifying the clinical value of novel biological
pathways involved in coronary heart disease (CHD)
may not only reveal new therapeutic targets but
also improve risk stratiﬁcation in secondary preven-
tion. The high rate of cardiovascular (CV) death and
the substantial heterogeneity in risk proﬁles among
CHD groups underline the importance of a personal-
ized approach to secondary prevention (1). Identi-
fying blood-based biomarkers offering independent
prognostic value and signiﬁcant reclassiﬁcation abil-
ity could be tremendously helpful in risk stratiﬁca-
tion and appropriate management.SEE PAGE 917
event(s)
MI = myocardial infarction
= pulse-wave velocityCumulative evidence suggests that diseases caused
by age-related chronic sterile inﬂammation, such as
atherosclerosis and Alzheimer disease, may not only
share genetic and environmental risk factors but also
have common molecular mechanisms (2). Amyloid-
beta 1-40 (Abeta40) peptides are generated by proteo-
lytic cleavage of the amyloid precursor protein (APP) by
beta- and gamma-secretases (3). Increasing evidence
from mouse models points toward a central role for
APP and Abeta40 in vascular inﬂammation patho-
physiology (4–8). Abeta40 activates a cascade of
proinﬂammatory events in endothelial cells and mac-
rophages involving cytokine secretion and oxidative
stress leading to vascular disease (6,9,10). Although
Abeta40 is the predominant amyloid-beta peptide
found in human atherosclerotic lesions (11), its clinical
value has not been investigated in patients with
CHD. We hypothesized that the proinﬂammatory
potential of Abeta40 peptide may be associated with
the clinical manifestation of atherosclerosis in humans
and with major adverse cardiac events (MACE).
This study’s primary aim was to evaluate the pre-
dictive value of Abeta40 blood levels in 2 indepen-
dent cohorts of patients with stable CHD and assess
the association of Abeta40 levels with incident CHD
as well as the extent and progression of subclinical
atherosclerosis.Atherosclerosis and Vascular Disease. All other authors have reported that th
this paper to disclose.The ﬁrst 3 authors contributed equally to this work.
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Manuscript received May 9, 2014; revised manuscript received December 9,METHODS
The present study involved 3 prospective and
2 case-control cohorts comprising 1,464 pa-
tients in hemodynamically stable condition
who had been recruited in 3 European CV
centers. First, patients undergoing diagnostic
coronary angiography at the German Heart
Centre in Munich (n¼ 514) were consecutively
recruited, as previously described (12). The
prospective part of the Munich cohort con-
sisted of 321 consecutive patients with angio-
graphically conﬁrmed stable CHD who were
followed for a median of 49.1 months for
MACE. Patients with a normal coronary
angiogram recruited during the same time
period were used as controls (n ¼ 193). The
Athens cohort consisted of 556 consecutive
patients age <75 years with creatinine levels
of <2 mg/dl and stable CHD followed for a
median of 61 months for MACE, as previously
described (13). The third prospective cohort consisted
of young healthy subjects without clinically overt CHD
whohas arterial stiffness and Abeta40 levels evaluated
at baseline and after a 5-year follow-up period (n ¼
107). Finally, the peripheral atherosclerosis assess-
ment cohort (n ¼ 394) was an ambulatory case-control
cohort including patients without clinically overt CHD
(control subjects; n ¼ 272) and patients with angio-
graphically veriﬁed stable CHD (cases; n ¼ 122). Pa-
tients with acute coronary syndrome (ACS), acute or
chronic inﬂammatory conditions, infection, cancer, or
stroke were not included in any of the cohorts. The
local ethics committee of each university center
approved the individual cohort studies, and patients
provided written informed consent.
Blood samples for Abeta40 measurement were
obtained as described in the Online Appendix. Plasma
concentrations of high-sensitivity C-reactive protein
(hsCRP) and high-sensitivity troponin T (hsTnT) were
measured as previously described (12). All laboratory
measurements were performed by experienced staff
blinded to clinical characteristics. Peripheral athero-
sclerosis was assessed (14), and a detailed description of
the assessment is available in the Online Appendix.
STATISTICAL ANALYSIS. We used multivariable Cox
proportional hazardmodels to examine the association
PWVey have no relationships relevant to the contents of
ntin Fuster.
r. Valentin Fuster.
2014, accepted December 14, 2014.
TABLE 1 Characteristics of CHD Cohorts
Overall 1st Quartile 2nd Quartile 3rd Quartile 4th Quartile p Value*
Munich cohort (subcohort with angiographically conﬁrmed CHD; n ¼ 321)
Participants, n 321 83 78 80 80
Mean plasma Abeta40, pg/ml 114.9 (29.8) 84.1 (13.1) 104.7 (3.5) 117.9 (4.7) 153.7 (27.4) <0.001
Mean age, yrs 67.2 (9.9) 62.5 (10.4) 64.6 (8.6) 68.5 (8.8) 73.3 (8.3) <0.001
Female 75 (23.4) 14 (16.9) 8 (10.3) 29 (36.3) 24 (30) <0.001
CV risk factors
Hypertension 22 (69.2) 50 (60.2) 55 (70.5) 61 (76.3) 56 (70) 0.166
Diabetes mellitus 99 (30.8) 25 (30.1) 22 (28.2) 27 (33.8) 25 (31.3) 0.897
Smoking 34 (10.6) 15 (18.1) 7 (9) 9 (11.3) 3 (3.8) 0.028
Family history of CHD 138 (43) 36 (43.4) 36 (46.2) 37 (46.3) 29 (36.3) 0.272
Clinical parameters
SBP, mm Hg 151 (28.4) 148 (27.4) 148 (23.2) 160 (26.8) 152 (34.1) 0.051
Cholesterol, mg/dl 181 (42.5) 183 (41.2) 184 (49.1) 184 (40.7) 173 (38.7) 0.302
HDL cholesterol, mg/dl 52.2 (14.5) 52.9 (14.8) 52.5 (13.3) 53.5 (16.2) 50 (13.5) 0.472
LDL cholesterol, mg/dl 100 (37.2) 104 (39) 103 (40.1) 99.2 (33.9) 95.2 (35.6) 0.452
Median CRP, mg/l (IQR) 1.69 (3.12) 1.56 (2.80) 1.68 (2.73) 1.61 (2.34) 2.51 (5.34) 0.058
Median eGFR, ml/min/1.73 m2 (IQR) 88 (42.1) 100 (38.8) 93.4 (27.9) 85.3 (37.4) 59.6 (33.8) <0.001
LVEF, % 56.3 (9.4) 56.3 (10.2) 57 (8.9) 57.6 (8.6) 54.3 (9.7) 0.129
CV endpoints
CV death 22 (6.9) 4 (4.8) 1 (1.3) 3 (3.8) 14 (17.5) <0.001
CV death and AMI 28 (8.8) 7 (8.4) 2 (2.6) 3 (3.8) 16 (20.0) <0.001
Extended composite endpoint 59 (18.4) 14 (16.9) 8 (10.3) 8 (10.1) 29 (36.2) <0.001
CV drugs
Antiplatelets (aspirin/clopidogrel) 320 (99.7) 82 (98.8) 78 (100) 80 (100) 80 (100) 0.668
Beta-blockers 314 (97.8) 80 (96.4) 77 (98.7) 78 (97.5) 79 (98.8) 0.692
ARB/ACE-I 307 (95.6) 79 (95.2) 73 (93.6) 77 (96.2) 78 (97.5) 0.668
Statins 316 (98.4) 83 (100) 77 (98.7) 79 (98.8) 77 (96.2) 0.271
Continued on the next page
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906between continuous and quartile-based Abeta40
levels and incident outcome events. Multivariable
survival models for main endpoints were built under a
bootstrap resampling procedure. Hazard ratios (HRs)
and CI were expressed per 1-pg/ml Abeta40 increase as
well as highest versus lowest Abeta40 quartile incre-
ment. We calibrated the multivariable survival models
with the likelihood ratio test and the Akaike and Bayes
information criteria. The incremental reclassiﬁcation
value of Abeta40 over conventional predictors of CV
death was assessed by category-free continuous net
reclassiﬁcation improvement (NRI), categorized NRI
(risk for CV death: low <6%, intermediate 6% to 9%,
high >9%), and integrated discrimination improve-
ment (IDI), which integrates the NRI over all possible
cutoffs and is equivalent to the difference in dis-
crimination slopes, over different models, using
established risk factors. Lack of substantial population
heterogeneity for all models assessing CV death was
conﬁrmed by adjustment for cohort origin in all
multivariate models and by random-effects model
used in pooled analysis. All tests were 2-tailed, and
results were considered statistically signiﬁcant for p
values <0.05. All statistical analyses were performed
using SPSS 21 (IBM Corporation, Armonk, New York)and Stata 11.1 (StataCorp LP, College Station, Texas). A
detailed description of the statisticalmethodology is in
the Online Appendix.
RESULTS
The study design is depicted in Figure 1. Associations
between baseline characteristics of the 2 CHD cohorts
in stable condition and quartiles of Abeta40 are shown
in Table 1. Age, hsCRP level, hsTnT level, estimated
glomerular ﬁltration rate (eGFR), and left ventricular
ejection fraction (LVEF) progressively increased
among Abeta40 quartiles. The incidence of CV death
was signiﬁcantly increased at the highest Abeta40
quartile compared with the other quartiles in both
CHD cohorts in stable condition (p < 0.001) (Table 1,
Figures 2A and 2B). Similarly, the incidence of com-
bined CV death and nonfatal acute myocardial infarc-
tion (MI) and incidence of the extended composite
endpoint (CV death, nonfatal acute MI, rehospitaliza-
tion due to ACS or myocardial revascularization) were
also increased at the highest quartile of Abeta40 in
both cohorts (p < 0.001) (Table 1). Abeta40 remained a
signiﬁcant independent predictor for CV death and
MACE after multivariable adjustment for age, sex,
TABLE 1 Continued
Overall 1st Quartile 2nd Quartile 3rd Quartile 4th Quartile p Value*
Athens cohort (n ¼ 556)
Participants, n 556 139 139 139 139
Median serum Abeta40, pg/ml (IQR) 36.4 (25.3) 15.5 (6) 28.9 (5.9) 41.2 (5.8) 80.1 (92.1) <0.001
Mean age, yrs 62.2 (9.3) 60.6 (9.1) 62.7 (10) 62.4 (9.1) 62.9 (8.6) 0.153
Female 91 (16.5) 26 (18.7) 21 (15.1) 21 (5.3) 23 (16.7) 0.843
CV risk factors
Hypertension 369 (66.4) 84 (60.4) 88 (63.3) 99 (71.2) 98 (70.5) 0.127
Diabetes mellitus 198 (35.6) 42 (30.2) 47 (33.8) 53 (38.1) 56 (40.3) 0.316
Smoking 158 (28.4) 33 (23.7) 45 (32.3) 42 (30.2) 38 (27.3) 0.394
Family history of CHD 198 (35.6) 52 (37.4) 47 (33.8) 47 (33.8) 52 (37.4) 0.724
Clinical parameters
SBP, mm Hg 130 (19.5) 130 (22.5) 131.2 (16.6) 130 (20.5 130 (17.8) 0.942
Cholesterol, mg/dl 168 (40.3) 173 (36.8) 170 (43.4) 160 (41.6) 162 (38.7) 0.115
HDL cholesterol, mg/dl 42.6 (10.8) 45.2 (10.2) 43.7 (10.1) 41.5 (10.9) 40 (11.2) <0.001
LDL cholesterol, mg/dl 96.4 (33.8) 99 (33.3) 98.7 (38.2) 96.4 (34.2) 91.6 (29.9) 0.244
BMI, kg/m2 28.66 (4.64) 28.54 (3.96) 28.95 (5.81) 28.76 (4.13) 28.4 (4.43) 0.788
Median CRP, mg/l (IQR) 2.36 (4.92) 1.86 (3.30) 2.19 (3.63) 2.54 (5.23) 3.37 (7.60) 0.09
LVEF, % 50.6 (11.3) 52.7 (10.2) 51.6 (10) 50.6 (12) 47.7 (12.3) 0.006
Number of vessels
1 208 (37.4) 61 (43.9) 58 (41.7) 52 (37.4) 37 (26.6) 0.12
2 185 (33.3) 38 (27.3) 46 (33.1) 48 (34.5) 53 (38.1)
3 159 (28.6) 40 (28.8) 35 (25.2) 39 (28.1) 45 (32.4)
CV endpoints
CV death 55 (10.7) 7 (5.2) 13 (9.8)) 13 (9.8) 22 (19.5) 0.004
CV death and AMI 116 (22.7) 21 (15.7) 22 (16.7) 39 (29.3) 34 (30.1) 0.004
Extended composite endpoint 198 (38.7) 46 (34.3) 38 (28.8) 61 (45.9) 53 (46.9) 0.006
CV drugs
Antiplatelets (aspirin/clopidogrel) 487 (90.7) 129 (94.9) 120 (90.2) 121 (91.0) 117 (86.7) 0.143
Beta-blockers 422 (81.9) 107 (80.5) 102 (80.3) 105 (82.7) 108 (84.4) 0.805
ARB/ACE-I 383 (73.2) 92 (69.2) 94 (73.4) 98 (76.0) 99 (74.4) 0.634
Statins 407 (86.6) 106 (86.9) 104 (88.1) 94 (82.5) 103 (88.8) 0.491
Values are n (%) or mean  SD unless otherwise indicated. Abeta40 levels for the Munich cohort are expressed as mean  SD and for the Athens cohort as median (IQR). *As
derived from 1-way analysis of variance for continuous variables or chi-square test for nominal variables. The Kruskal-Wallis test was used for continuous variables deviating
from normality.
Abeta40 ¼ amyloid-b 1-40 peptide; ACE-I ¼ angiotensin-converting enzyme inhibitor; AMI ¼ acute myocardial infarction; ARB ¼ angiotensin receptor blocker; BMI ¼ body
mass index; CAD ¼ coronary artery disease; CHD ¼ coronary heart disease; CRP ¼ C-reactive protein; CV ¼ cardiovascular; eGFR ¼ estimated glomerular ﬁltration rate;
HDL ¼ high-density lipoprotein; IQR ¼ interquartile range; LDL ¼ low-density lipoprotein; LVEF ¼ left ventricular ejection fraction; SBP ¼ systolic blood pressure.
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907LVEF, and hsCRP level (HR per 1-pg/ml increase for CV
death in Munich cohort: 1.023; 95% CI: 1.007 to 1.039;
p < 0.05; Athens cohort: 1.038; 95% CI: 1.018 to 1.057;
p < 0.001) (Table 2). After additional adjustment for
eGFR and hsTnT level, which were available for the
Munich cohort, Abeta40 remained a signiﬁcant inde-
pendent predictor of all endpoints.
Taking into consideration that the statistical anal-
ysis in the individual cohorts offered similar results,
we sought to assess whether Abeta40 levels improved
model calibration for risk prediction and correctly
reclassiﬁed risk for CV death and other CV events
over the best predictive model. Because the number
of adverse events per cohort was inadequate to
perform such an analysis in each cohort, we created a
combined CHD cohort from the quartiles of the
Munich and Athens cohorts (n ¼ 877). As described inthe Online Appendix, we found no evidence of sub-
stantial heterogeneity between the 2 cohorts. Online
Table 1 contains the descriptive characteristics of
the combined total CHD cohort.
During the follow-up period of 4.4 years, patients
experienced 77 CV deaths, 144 cumulative CV deaths
and nonfatal acute MIs, and 257 MACE events in the
total CHD cohort. In a univariate model, the cumu-
lative incidence of CV death, as well as the secondary
and extended composite endpoints, was signiﬁcantly
associated with increasing quartiles of Abeta40
(Figure 2C, Online Table 1). Abeta40 remained a sig-
niﬁcant predictor for CV death, as well as for sec-
ondary endpoints after multivariable adjustments for
predictors of CV death (age, sex, LVEF, hsCRP level;
HR of the highest quartile vs. lowest quartile: 3.02;
95% CI: 1.51 to 6.04; p < 0.001) (Online Table 2). After
FIGURE 1 Study Flow Chart
1. Association of Aβ40 with
incident CHD and CV mortality and
MACE after a median follow-up
period of 4.1 years
2. Association of Aβ40 with CV
mortality and MACE after a median
follow-up period of 5 years
3. Calibration and reclassification
over established risk factors for
recurrent CV disease
5. Association of Aβ40 with
different stages of atherosclerosis
(subclinical peripheral
atherosclerosis and CAD)
394 consecutive patients
undergoing peripheral
atherosclerosis assessment
Atherosclerosis
assessment cohort
107 consecutive healthy young
subjects without evident CV
disease and available arterial
stiffness assessment at baseline
and at 5-year follow-up period
Healthy subjects
514 consecutive patients
undergoing elective coronary
angiography including 321
consecutive patients with stable CAD
(Lost to follow-up n=1)
Munich CAD Cohort Objectives
4. Association of Δ Aβ40 with Δ
arterial stiffness
Study Design: Cross-sectional part
Study Design: Prospective part
556 consecutive patients with
stable CAD (Athens Attikon
cohort)
(Lost to follow-up n=45)
Athens CAD Cohort
Quartile based analysis
of 877 patients with stable CAD
(derived from the previous cohorts
with median follow-up 4.4 years)
Total CAD cohort
Flow chart of the study design showing the prospective and cross-sectional parts of the
study. Ab40 ¼ amyloid-beta 1-40 peptide; CAD ¼ coronary artery disease; CHD ¼ coronary
heart disease; CV ¼ cardiovascular; MACE ¼ major adverse cardiac event(s).
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908additional adjustment for traditional risk factors over
the best predictive model, these results did not sub-
stantially change.
Similar associations were observed in an analysis
using Abeta40 as a standardized continuous variable
(Online Table 3). As shown in Table 3, Abeta40
signiﬁcantly improved model calibration over the
best predictive model for all 3 prospective endpoints
(likelihood ratio test p < 0.001). Next, we addressed
whether Abeta40 correctly reclassiﬁed risk of
patients with stable CHD, thus predicting CV end-
points. Applying a category-free continuous NRI,category-based NRI for CV death (4.4-year risk cate-
gories <6%, 6% to 9%, and >9%), and IDI, we
observed that Abeta40 correctly and signiﬁcantly
reclassiﬁed patients from lower to higher risk and
vice versa better than age, sex, and LVEF (Table 3).
Abeta40 improved reclassiﬁcation (continuous NRI)
even when hsCRP level was added to the adjustment
model (NRI 36.7% for CV death; p < 0.001). Similarly,
Abeta40 offered a signiﬁcant IDI after adjustment for
CV death predictors (p < 0.001). Similar results were
obtained for CV death and nonfatal acute MI (sec-
ondary endpoint) and for the extended composite
endpoint (Table 3). When the reclassiﬁcation analysis
was adjusted for cohort origin, these results did not
change (data not shown). When reclassiﬁcation
analysis was performed for continuous standardized
Abeta40, these results did not substantially change
either (Online Table 4).
ARTERIAL STIFFNESS. Arterial stiffness measured by
pulse-wave velocity (PWV) is a marker of early
vascular disease progression. It is not known if
Abeta40 is involved in arterial stiffening. Thus, we
evaluated the possible association of Abeta40 with
arterial stiffness progression (on the basis of PWV)
over time. The descriptive characteristics of the 107
apparently healthy individuals, who were followed
for 5 years, are shown in Online Table 5, and changes
of PWV over time are graphically shown in Online
Figure 1. At each visit (baseline and follow-up),
detailed risk assessments and PWV measurements
were performed. Abeta40 levels were signiﬁcantly
increased after 5-year follow-up (26.1  18.5 pg/ml vs.
43.7  25.3 pg/ml; p < 0.001). By linear mixed-model
analysis, changes in plasma Abeta40 levels during
this follow-up were independently associated with
concomitant changes in calculated CV risk (Heart-
score; p ¼ 0.008) and PWV (p ¼ 0.006) (Online
Table 6) in the same direction.
To evaluate the association of Abeta40 with
different stages of atherosclerosis in various arte-
rial beds, we measured Abeta40 plasma levels in a
cohort of 394 consecutive subjects who underwent
peripheral atherosclerosis assessment (baseline
characteristics in Online Table 7). Plasma Abeta40
levels signiﬁcantly correlated with markers of sub-
clinical atherosclerosis (Figure 3). After adjustment
for traditional risk factors (age, sex or eGFR, arterial
hypertension, hyperlipidemia, body mass index,
smoking, diabetes mellitus), Abeta40 levels inde-
pendently correlated with common carotid intima-
media thickness (IMT) (odds ratio: 2.078; 95% CI:
1.089 to 3.966; p ¼ 0.027), lower ankle brachial index
(beta ¼ 0.211; p ¼ 0.005), and a higher probability for
increased atheromatous burden in the carotid or
FIGURE 2 Cumulative Probability of Death According to Quartile of Abeta40 Plasma Levels in Patients With CAD
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The Kaplan-Meier survival analysis shows that patients belonging to the highest quartile of Abeta40 had the highest probability of death compared with patients in other
quartiles in the Munich (A) (p < 0.001) and Athens (B) (p ¼ 0.002) cohorts, respectively. (C) The combined total cohort consists of all patients with CAD (n ¼ 877)
derived from the Munich and Athens cohorts. The Kaplan-Meier survival analysis shows that patients belonging to the highest quartile of Abeta40 had the highest
probability of death compared with patients belonging to the other quartiles (p < 0.001). Abbreviations as in Figure 1.
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909femoral arteries as expressed by the number of pla-
ques per patient (p ¼ 0.043). Moreover, an increased
burden of subclinical atherosclerosis, including
increased IMT, involvement of at least 2 arterial beds
or at least 3 peripheral sites with plaques, or presence
of CHD, was associated with higher levels of Abeta40
compared with no evidence of subclinical athero-
sclerosis or minor involvement (Figure 3). After
adjustment for traditional risk factors and eGFR as
described above, these differences remained signiﬁ-
cant (p < 0.05).
Cross-sectional analysis of the Munich cohort also
revealed that the incidence of angiographically
conﬁrmed CHD was positively associated with
Abeta40 quartiles (Online Table 7). Abeta40 plasma
concentration was higher in patients with CHD evenafter adjustment for traditional risk factors (age, sex,
type 2 diabetes mellitus, smoking, hypertension, and
hyperlipidemia; p ¼ 0.025) or Framingham risk score
(p ¼ 0.009). After additional adjustment for hsCRP
level, eGFR <60 ml/min/1.73 m2, and hsTnT level,
Abeta40 remained signiﬁcantly associated with CHD
(p ¼ 0.028).
DISCUSSION
We investigated the clinical relevance of Abeta40
blood levels in 2 cohorts of patients with stable CHD
who were followed for CV death and MACE for a
median of 4.4 years. After adjustment for clinical
predictors, Abeta40 was independently associated
with the risk of CV death or MACE. The results were
TABLE 2 Univariate and Multivariate Analysis of Abeta40 as a Predictor of Study Endpoints
HR per 1-pg/ml Increase (95% CI) HR Lowest to Highest Quartile (95% CI) HR Plot Lowest to Highest Quartile (95% CI)
CV death
Munich cohort (n ¼ 321)
Univariate 1.027 (1.017–1.038)* 6.3 (2.7–15.1)*
Model 1 1.024 (1.009–1.04)†‡ 4.01 (1.59–10.1)†
1.02 (1.007–1.034)†§ 3.57 (1.3–9.86)†§
Model 2 1.024 (1.008–1.04)†‡ 3.83 (1.53–9.63)†
1.021 (1.003–1.04)†‡§ 3.54 (1.27–9.84)†§
Model 3 1.023 (1.007–1.039)†‡ 3.48 (1.36–8.89)†
1.021 (1.003–1.04)†‡§ 3.34 (1.17–9.51)†§
Athens cohort (n ¼ 556)
Univariate 1.037 (1.02–1.056)* 4.25 (1.81–9.97)*
Model 1 1.038 (1.019–1.057)* 3.84 (1.64–9.02)†
Model 2 1.041 (1.021–1.061)* 3.57 (1.51–8.4)†
Model 3 1.038 (1.018–1.057)* 3.22 (1.36–7.65)†
Secondary composite endpoint (CV death and/or AMI)
Munich cohort
Univariate 1.023 (1.013–1.032)* 5.12 (2.37–11.03)*
Model 1 1.019 (1.006–1.032)†‡ 3.64 (1.6–8.25)†
1.014 (1.002–1.026)†§ 2.95 (1.2–7.25)†§
Model 2 1.019 (1.006–1.033)†‡ 3.49 (1.54–7.9)†
1.015 (1.00–1.03)‡§ 2.92 (1.18–7.21)†§
Model 3 1.019 (1.005–1.034)†‡ 3.33 (1.44–7.68)†
1.015 (1.00–1.031)‡§ 2.86 (1.13–7.19)†§
Athens cohort
Univariate 1.039 (1.024–1.055)* 2.73 (1.56–4.78)*
Model 1 1.039 (1.023–1.054)* 2.71 (1.55–4.75)*
Model 2 1.041 (1.025–1.057)* 2.66 (1.52–4.66)†
Model 3 1.037 (1.022–1.053)* 2.55 (1.44–4.54)†
Continued on the next page
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TABLE 2 Continued
HR per 1-pg/ml Increase (95% CI) HR Lowest to Highest Quartile (95% CI) HR Plot Lowest to Highest Quartile (95% CI)
Extended composite endpoint (CV death, AMI, rehospitalization for ACS, coronary revascularization)
Munich cohort
Univariate 1.022 (1.015–1.03)* 3.91 (2.3–6.57)*
Model 1 1.019 (1.011–1.027)* 3.05 (1.74–5.34)*
1.017 (1.008–1.027)*§ 2.85 (1.58–5.14)†§
Model 2 1.018 (1.01–1.027)* 2.92 (1.67–5.11)†
1.018 (1.008–1.027)*§ 2.82 (1.55–5.11)†§
Model 3 1.016 (1.005–1.027)†‡ 2.69 (1.51–4.81)†
1.016 (1.006–1.026)†§ 2.71 (1.48–4.97)†§
Athens cohort
Univariate 1.039 (1.026–1.053)* 2.24 (1.49–3.36)*
Model 1 1.039 (1.026–1.052)* 2.28 (1.52–3.42)*
Model 2 1.041 (1.028–1.055)* 2.24 (1.49–3.36)*
Model 3 1.038 (1.025–1.052)* 2.14 (1.41–3.25)*
Model 1: age and sex (or eGFR indicated by §) Model 2: age, sex (or eGFR indicated by §). and LVEF. Model 3: age, sex (or eGFR indicated by §), LVEF, and high-sensitivity CRP
and high-sensitivity Troponin-T (available only in Munich cohort). eGFR was not inserted in models with age and sex because these parameters are included in its equation.
*Observed statistical signiﬁcance p < 0.001. †Observed statistical signiﬁcance p < 0.05. ‡CI are calculated under resampling (bootstrapping with 1,000 replications).
ACS ¼ acute coronary syndrome; HR ¼ hazard ratio per 1-unit increase in Abeta40 or transition from lowest to highest quartile in Abeta40; other abbreviations as in Table 1.
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911virtually identical between the 2 cohorts. The current
ﬁndings suggest that high levels of Abeta40 may help
identify patients at increased risk of CV events.
Further, we addressed the association of Abeta40
levels with subclinical atherosclerosis in 2 additional
cohorts. We found that alterations in Abeta40 levels
after 5-year follow-up were independently associated
with aortic stiffness progression. Moreover, blood
levels of Abeta40 were independently associated
with the extent of arteriosclerotic disease, including
arterial stiffness, incident IMT, incident peripheral
arterial atherosclerotic plaques, and CHD.
Abeta40 plasma levels were associated with aging
in all of the study cohorts, in accordance with previ-
ous reports (15). However, Abeta40 correlated with
CV events independently of aging and eGFR, vari-
ables well known to affect its levels, reﬂecting
the fact that a multifactorial regulatory network
is responsible for Abeta40 clearance from blood
including kidney, liver, and peripheral tissue degra-
dation by a plethora of proteases (16). Abeta40 levels
correlated with the presence of angiographic CHD aswell as the presence, extent, and progression of
subclinical peripheral atherosclerosis, conﬁrming
experimental evidence that APP and Abeta40 are
critically involved in vascular inﬂammation. Abeta40
activates numerous vascular cells, leading to vascular
inﬂammation, as depicted in the Central Illustration.
Taking into consideration that Abeta40 was an inde-
pendent predictor of changes in arterial stiffness after
5-year follow-up in a healthy cohort, this peptide may
contribute to vascular aging and progression of pre-
clinical arterial damage long before clinically
evident CV disease is established. This ﬁnding con-
curs with recent evidence showing that arterial stiff-
ness was associated with cerebral amyloid-beta
deposition over a 2-year follow-up in elderly adults
without dementia and implies that increased circu-
lating Abeta40 levels may be the linking mechanism
in this association (17). Given that arterial stiffness as
an early marker of arteriosclerosis is closely associ-
ated with adverse CV events (18), it is tempting to
hypothesize that Abeta40 also may predict MACE in
the general population.
TABLE 3 Improvement in Model Calibration and Reclassiﬁcation of Abeta40 Over Best Predictive Model for Endpoints
Calibration Parameters Reclassiﬁcation Parameters
LR Test Continuous NRI
p Value
NRI
(SE)†
IDI
AIC (BIC)
LR Chi-Square
(p Value)
Among Event
Subjects
Among Nonevent
Subjects
Overall
(95% CI)*
Coefﬁcient
(SE)
Primary endpoint (CV death; n ¼ 77)
Model 1 986.1 (995.5) 15.1
(<0.001)
35.06% 12.04% 47.1%
(24–70.4)
<0.001 12%
(5.9)‡
1.85
(0.57)§þ Abeta40 973 (987.1)
Model 2 969.5 (983.6) 14.2
(<0.001)
35.06% 9.1% 44.2%
(24–70)
0.001 22.2%
(7.1)‡
2.01
(0.64)§þ Abeta40 957.3 (976.2)
Model 3 956.7 (975.5) 11.9
(0.001)
27.28% 10.68% 36.7%
(12.5–60.7)
0.001 22.4%
(7)‡
1.92
(0.62)§þ Abeta40 946.7 (970.3)
Secondary composite endpoint (CV death and AMI; n ¼ 144)
Model 1 1,740 (1,750) 23.95
(<0.001)
29.16% 11.3% 40.5%
(21.1–59.8)
<0.001 6.1%
(3.1)‡
1.65
(0.45)§þ Abeta40 1,718 (1,733)
Model 2 1,735 (1,749) 23.86
(<0.001)
30.56% 9.84% 40.4%
(21.9–58.9)
<0.001 13.2%
(5.4)‡
1.67
(0.44)§þ Abeta40 1,713 (1,732)
Model 3 1,689 (1,708) 22.23
(<0.001)
30.5% 10.1% 40.4%
(20.3–60.5)
<0.001 14.1%
(5.4)‡
1.67
(0.45)§þ Abeta40 1,669 (1,692)
Extended composite endpoint (CC death, AMI, rehospitalization for ACS, coronary revascularization; n ¼ 257)
Model 1 3,000 (3,010) 28.6
(<0.001)
19.84% 9.86% 29.7%
(15.3–44.1)
<0.001 7.2%
(1.43)
1.62
(0.45)§þ Abeta40 2,974 (2,988)
Model 2 2,988 (3,002) 28.66
(<0.001)
19.04% 9.16% 29%
(12.7–45.3)
<0.001 16.8%
(5.7)‡
1.52
(0.43)§þ Abeta40 2,961 (2,980)
Model 3 2,913 (2,932) 25.49
(<0.001)
20.16% 8.3% 28.5%
(12.4–44.5)
0.002 21%
(5.6)§
1.36
(0.41)‡þ Abeta40 2,890 (2,913)
Model 1: age and sex. Model 2: age, sex, and LVEF. Model 3: age, sex, LVEF, and CRP. All models were built using the bootstrap resampling procedure. *95% CI are provided
under resampling (bootstrapping with 1,000 replications). †Category-based NRI: CV death: low risk <6%, moderate risk 6% to 9%, high risk >9%; CV death and ACS: low
risk <16%, moderate risk 16% to 20%, high risk >20%; extended composite endpoint: low risk <28%, moderate risk 28% to 35%, high risk >35%. ‡p < 0.05. §p < 0.001.
AIC ¼ Akaike information criterion; BIC ¼ Bayesian information criterion (AIC and BIC are unitless. Smaller values indicate better ﬁt to data when compared with nested
models.); IDI ¼ integrated discrimination index; LR chi-square: twice the difference in log likelihoods between nested models under chi-square distribution with 1 degree of
freedom; LR test ¼ likelihood ratio test; NRI ¼ net reclassiﬁcation index; other abbreviations as in Tables 1 and 2.
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912CLINICAL IMPLICATIONS. Clinical guidelines under-
line the importance of novel biomarker development
in speciﬁcally addressing the incremental diagnostic
and prognostic beneﬁt derived beyond that of estab-
lished risk factors. Multiple pathways contribute to
atherogenesis, atheroprogression, and plaque insta-
bility, leading ultimately to thrombosis. Current
efforts focusing on biomarker development try to
address risk stratiﬁcation reﬁnement by adding
information from biomarkers that reﬂect distinct
pathways involved in vascular inﬂammation com-
plementing traditional predictive models. Our data
indicated that patients in the highest Abeta40 quar-
tile had a risk of CV death more than 3 times as great
and a risk of MACE more than 2 times as great as
patients in the lowest quartile. Interestingly, a
nongraded response of Abeta40 in association with
CV events was observed, being strongest in the
highest quartile. Given that we found equally strong
correlations with Abeta40 as a continuous variable
and that we adjusted for all known commonly
used confounders, this nongraded response may
be attributed either to residual confounding ofunknown factors or to speciﬁc biological attributes
of Abeta40.
Our results suggest that a threshold concentration
of Abeta40 (highest quartile) exists that differentiates
patients with events, probably reﬂecting Abeta40
oligomer formation. Much more toxic to cells than
Abeta40 monomers, Abeta40 oligomers are formed
under conditions of Abeta40 monomer accumulation
(19,20). Irrespective of response type, several mech-
anisms may explain a causal relationship of high
Abeta40 levels with the ultimate step in cardiac
events such as Abeta40-mediated platelet aggrega-
tion (21) and arrhythmogenesis (22), as well as release
of matrix metalloproteinase 9 and increased plaque
vulnerability (8,23). Using contemporary statistical
techniques that are considered prerequisites for
biomarker validation, such as model calibration and
reclassiﬁcation markers, we report here for the ﬁrst
time the use of Abeta40 as a tool for reﬁning CV risk
prediction in patients with stable CHD. Notably, this
study provides the ﬁrst evidence that higher Abeta40
levels were associated with a worse CV outcome in
patients with stable CHD, even after adjustment for
FIGURE 3 Abeta40 Plasma Levels and Subclinical Atherosclerosis and CHD
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Aβ40 levels are associated with IMT Aβ40 levels are associated with number of plaques
Aβ40 levels are associated with extent of atherosclerosis
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C
Compared with patients with stable CHD, mean plasma levels of Abeta40 rose (A) in subjects with increased common carotid intima-media thickness (IMT >0.9 mm),
(B) across increasing number of atherosclerotic plaques in the carotid and femoral arteries, and (C) across increasing scores of atherosclerosis. All p values were
calculated by analysis of variance with Bonferroni post-hoc tests among groups using log transformed Abeta40 values. Abbreviations as in Figure 1.
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913hsCRP, a well-established inﬂammatory biomarker.
The assessment of Abeta40 as a biomarker may be
useful for identifying subgroups who would beneﬁt
from additional diagnostic testing, an aggressive
treatment of modiﬁable risk factors, or less intensive
medical surveillance and therapy.
Our ﬁndings should trigger further research
assessing Abeta40 as a potential therapeutic target for
secondary CV prevention. Statins and antihyperten-
sive therapy already have been shown to affect
Abeta40 levels (24–27). Statins have reduced the pro-
duction of Abeta40 in several cell culture and animal
studies (25). Considering the detrimental effects of
Abeta40 on CV disease, further studies are needed
to assess whether statins exert their beneﬁcial pleio-
tropic effects partially through regulation of Abeta40production or clearance. Similarly, research is needed
to assess the effect of some antihypertensive drugs,
given that angiotensin receptor blockers may decrease
Abeta40 concentrations in the brain (24,26), whereas
furosemide, nitrendipine, and candesartan prevent
oligomerization of Abeta40 in vitro (27).
STUDY LIMITATIONS. Circulating levels of Abeta40
were not comparable among the study cohorts, prob-
ably due to methodological differences in storage
conditions, which are known to affect Abeta40 stabil-
ity andﬁnal concentration (28,29). This limitation does
not allow derivation of reference cutoff values for
Abeta40 and poses difﬁculties in the joint assessment
of the 2 CHD cohorts. We addressed this issue by using
2 distinct methods of pooling of the individual values
(by quartiles and standardized continuous values).
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Stamatelopoulos, K. et al. J Am Coll Cardiol. 2015; 65(9):904–16.
Amyloid-beta 1-40 peptide (Abeta40) production depends on: 1) production of amyloid precursor protein (APP); 2) cleavage of APP to Abeta peptides;
3) clearance; and 4) degradation mechanisms. Abeta40 binds to a plethora of receptors on the surface of cells and activates downstream pathways. For
instance, binding of Abeta40 to platelet protease-activated receptor 1 (PAR1) induces downstream signaling affecting the thromboxane A2 (TXA2) signaling
pathway, reactive oxygen species (ROS) production, platelet degranulation, and Abeta40 release, leading to platelet activation, aggregation, and
thrombosis. Similarly, Abeta40 binding to smooth muscle cells or endothelial cells through appropriate receptors can ultimately lead to apoptosis along
different pathways. Taken altogether, there is abundant experimental evidence supporting the notion that Abeta40 may play a critical role in all stages of
atherosclerosis. 7nAChR ¼ alpha-7 nicotinic receptor; DR ¼ death receptor; LRP1 ¼ low-density lipoprotein receptor-related protein 1; NF-kB ¼ nuclear
factor-kappaB; RAGE ¼ receptor for advanced glycation end products; TLR ¼ toll-like receptor.
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914Larger studies are needed to determine a cutoff value
of Abeta40 levels in blood and its possible usage in
clinical practice. Our results need to be further vali-
dated and should not be extrapolated to the generalpopulation without suspected or known CHD. Addi-
tional studies in community-based cohorts are likely to
be valuable in determining the possible incremental
prognostic value of Abeta40 for CV events.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In patients
without clinically overt coronary heart disease, blood levels of
the proinﬂammatory peptide Abeta40 are associated with
subclinical atherosclerosis and progression of arterial stiffness,
independent of other conventional risk factors. Further, in
patients with stable coronary heart disease, blood levels of
Abeta40 are associated with cardiovascular mortality and
morbidity over 5 years, independent of other conventional risk
factors.
TRANSLATIONAL OUTLOOK: Further studies are warranted
to validate the predictive value of measuring blood levels of
Abeta40 in the general population, assess the effect of risk
reduction therapies on blood levels of Abeta40, and test the
safety and efﬁcacy of speciﬁc anti–amyloid-beta therapies in
patients with atherosclerosis.
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915Due to the limited sample size and number of CV
deaths in each individual CHD cohort, we could not
adjust for all biologically relevant risk factors in each
individual CHD cohort (such as all traditional risk fac-
tors); rather, we used bootstrapping and adjusted for
the best predictive model. Other potential limitations
include residual confounding by unknown or coexist-
ing conditions not ascertained at the time of blood
sampling. We addressed this limitation by further
adjusting the observed associations for all traditional
risk factors over the best predictive model in the large
combined CHD cohort. The consistently conﬁrmed
associations of Abeta40with surrogates of CV risk and/
or CV outcome and reclassiﬁcation indexes in 3 inde-
pendent prospective cohorts, as well as in the pooled
cohort, strongly supports the clinical utility of Abeta40
as a biomarker for secondary prevention.
CONCLUSIONS
The present study demonstrated that Abeta40 was
independently associated with the extent of human
atherosclerosis and substantially improved risk strat-
iﬁcation for CV death in patients with stable CHD.
Because the proinﬂammatory effects of Abeta40 can be
altered by established CV therapy, these ﬁndings may
provide a rationale for a novel anti-inﬂammatory
therapeutic target in patients with CHD. Whether
treatment aimed at reducing the extent of Abeta40-
induced vascular inﬂammation can positively alter
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